The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study
Abstract
Efavirenz (EFV) is associated with hyperlipidemia when used in combination with other antiretroviral drugs. EFV is a mixed inducer/inhibitor of cytochrome P450 (CYP) 3A4 isozyme and may interact with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that are primarily metabolized via CYP3A4. To assess the drug-drug interaction of EFV used in combination with simvastatin (SIM), atorvastatin (ATR), or pravastatin (PRA), an open-label trial was conducted in 52 healthy adult HIV-seronegative subjects across AIDS Clinical Trials Group sites in the United States. Subjects received 40 mg of SIM, 10 mg of ATR, or 40 mg of PRA daily on days 0 through 3 and days 15 through 18. EFV was administered daily at a dose of 600 mg on days 4 through 18. SIM, ATR, and PRA concentrations were determined before and after EFV, and EFV concentrations were determined before and after statins. EFV reduced SIM acid exposure (area under the curve at 0 to 24 hours [AUC0-24 h]) by 58% (Wilcoxon signed rank test, P=0.003) and active HMG-CoA reductase inhibitory activity by 60% (P<0.001). EFV reduced ATR exposure by 43% (P<0.001) and the total active ATR exposure by 34% (P=0.005). EFV administration resulted in a 40% decrease in PRA exposure (P=0.005). SIM, ATR, and PRA had no effect on non-steady-state EFV concentrations. In conclusion, EFV, when administered with SIM, ATR, or PRA, can result in significant induction of statin metabolism. The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527 · cited 5×
“SIM, a lactone prodrug of SIM acid, is the most lipophilic of the statins, and the drug is metabolized primarily by CYP3A4.”
BackgroundInfluentialRhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent Itraconazole
Lees, R. S., & Lees, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331015 · Cited by 136
Cited by
27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology
Nelson, E. R., Wardell, S. E., Jasper, J. S., Park, S., Suchindran, S., Howe, M. K., Carver, N. J., Pillai, R. V., Sullivan, P. M., Sondhi, V., et al. (2013) · Science · doi:10.1126/science.1241908 · Cited by 839
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
Aberg, J. A., Gallant, J. E., Ghanem, K. G., Emmanuel, P., Zingman, B. S., & Horberg, M. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit665 · Cited by 496
Self-citationThompson, M. A., Horberg, M. A., Agwu, A. L., Colasanti, J. A., Jain, M. K., Short, W. R., Singh, T., & Aberg, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1391 · Cited by 256
Self-citationLipodystrophy: pathophysiology and advances in treatment
Fiorenza, C. G., Chou, S. H., & Mantzoros, C. S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.199 · Cited by 255
Metadata
- Authors
- Gerber, J. G., Rosenkranz, S. L., Fichtenbaum, C. J., Vega, J. M., Yang, A., Alston, B. L., Brobst, S. W., Segal, Y., & Aberg, J. A.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2005-07-01
- Volume
- 39
- Issue
- 3
- Pages
- 307-312
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2064049784
- Cited by
- 167
- References
- 2
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study. https://app.cochat.ai/papers/10.1097/01.qai.0000167156.44980.33
- The paper
- Gerber, J. G., Rosenkranz, S. L., Fichtenbaum, C. J., Vega, J. M., Yang, A., Alston, B. L., Brobst, S. W., Segal, Y., & Aberg, J. A. (2005). Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/01.qai.0000167156.44980.33
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.